AAV Manufacturing: The benefits of growing serum-free, suspension HEK293 cells in the scale-X™ fixed-bed bioreactor
In this study, HEK293F cells grown in scale-X bioreactor produce >3x higher AAV-2 vector, with 25-52% lower cost than the reference process.
Related Content
New Strategies for a Better Glycosylation Profile
January 22nd 2025Article
Glycan analysis provides key information on critical quality attributes that could affect stability, safety and efficacy of a protein therapeutic. Specific needs for understanding the glycosylation profiles change throughout the drug development process, but the requirement for high-resolution glycan information remains the same and is essential to help ensure product quality.
